Intellectual Property

Caldera has protected our intellectual property around both the techniques (RBAS) and gene expression profiles for diagnosis/prognosis of prostate cancer by filing patent applications in the major OECD countries.

Caldera is currently  writing new patent applications to protect the process and biomarkers used in our non-invasive urine diagnostic test for prostate cancer.

Through the course of our development, Caldera has also accumulated considerable know-how and trade secrets that include both data and analytical tools.

Caldera’s Patent Numbers

Connect with us

Caldera welcomes discussions with potential collaborators, partners, patients and with clinicians. Please get in touch!

Contact us